Sellas Life Sciences Group Inc (SLS)

Apr 09, 2025

SELLAS reports promising AML treatment trial results - Investing.com

Apr 09, 2025

Apr 08, 2025

SELLAS posts mid-stage trial win for leukemia drug (SLS:NASDAQ) - Seeking Alpha

Apr 08, 2025

Apr 08, 2025

Sellas Life Sciences Says Group Data Show Tambiciclib Tops Benchmark for Median Overall Survival in Leukemia Study; Shares Up - MarketScreener

Apr 08, 2025

Apr 08, 2025

Sellas Life Sciences Shares Gains On Positive Cohort 3 Phase 2 Results For SLS009 - Nasdaq

Apr 08, 2025

Apr 08, 2025

SELLAS reports promising AML treatment trial results By Investing.com - Investing.com India

Apr 08, 2025

Apr 08, 2025

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML - GlobeNewswire

Apr 08, 2025

Apr 08, 2025

Breakthrough: New Leukemia Drug Shows 8.8-Month Survival vs 2.5-Month Standard - Stock Titan

Apr 08, 2025

Apr 05, 2025

Critical Review: SELLAS Life Sciences Group (NASDAQ:SLS) vs. CV Sciences (OTCMKTS:CVSI) - Defense World

Apr 05, 2025

Apr 02, 2025

Virtu Financial LLC Sells 38,086 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World

Apr 02, 2025

Mar 31, 2025

Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst (SLS) - Seeking Alpha

Mar 31, 2025

Mar 28, 2025

Solaris Resources (CVE:SLS) Cut to Hold at Maxim Group - Defense World

Mar 28, 2025

Mar 27, 2025

Sellas Life Sciences Advances in Cancer Treatment Development - TipRanks

Mar 27, 2025

Mar 26, 2025

Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail

Mar 26, 2025

Mar 21, 2025

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times

Mar 21, 2025

Mar 20, 2025

SELLAS LIFE SCIENCES GROUP I Earnings Results: $SLS Reports Quarterly Earnings - Nasdaq

Mar 20, 2025

Mar 20, 2025

SELLAS Life Sciences Group, Inc. SEC 10-K Report - TradingView

Mar 20, 2025

Mar 20, 2025

SELLAS Life Sciences Group Inc. (SLS) reports earnings - Quartz

Mar 20, 2025

Mar 20, 2025

SELLAS Life Sciences Group (SLS) to Release Earnings on Thursday - Defense World

Mar 20, 2025

Mar 08, 2025

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Update - Defense World

Mar 08, 2025

Feb 27, 2025

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 - The Malaysian Reserve

Feb 27, 2025

Feb 26, 2025

SELLAS Life Sciences Group Inc (NASDAQ: SLS) Drops -2.59% In Early Trade; What Lies Ahead? - Stocks Register

Feb 26, 2025

Feb 22, 2025

Biotech CEO predicts 'revolutionary' steps toward curing cancer on horizon thanks to AI - AOL

Feb 22, 2025

Feb 21, 2025

Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment - Yahoo Finance

Feb 21, 2025

Feb 21, 2025

SELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trial - MSN

Feb 21, 2025

Feb 20, 2025

SELLAS reports promising DLBCL treatment trial results By Investing.com - Investing.com Nigeria

Feb 20, 2025

Feb 20, 2025

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL - GlobeNewswire

Feb 20, 2025

Feb 20, 2025

3 AI Stocks Lawmakers Are Snapping Up Now - The Globe and Mail

Feb 20, 2025

Feb 20, 2025

SELLAS Reports Positive Phase 2a Data For SLS009 With Zanubrutinib In Relapsed/Refractory DLBCL - Nasdaq

Feb 20, 2025

Feb 20, 2025

SELLAS reports promising DLBCL treatment trial results - Investing.com

Feb 20, 2025

Feb 20, 2025

SELLAS Life Sciences Reports Promising Phase 2a Data for SLS009 in Combination with Zanubrutinib in DLBCL Patients - Nasdaq

Feb 20, 2025

Feb 12, 2025

SELLAS Life Sciences Group’s $25 Million Common Stock Offering - Global Legal Chronicle

Feb 12, 2025

Feb 10, 2025

SELLAS Life Sciences Group Inc (NASDAQ:SLS) stock crossing the finish line today - US Post News

Feb 10, 2025

Feb 10, 2025

Market Insight: SELLAS Life Sciences Group Inc (SLS)’s Notable Drop, Closing at 1.37 - The Dwinnex

Feb 10, 2025

Feb 10, 2025

Wall Street analysts’ outlook for SELLAS Life Sciences Group Inc (SLS) - SETE News

Feb 10, 2025

Feb 07, 2025

SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS) - MarketBeat

Feb 07, 2025

Feb 06, 2025

SELLAS Life Sciences Group Inc (NASDAQ: SLS) Stock Has Gained 38.89% Over The Month – Is There Room For Growth? – Marketing Sentinel - Marketing Sentinel

Feb 06, 2025

Feb 06, 2025

Orangekloud Technology Inc (NASDAQ: ORKT) Up 58.11% From 52-Week Low; YTD Falls -50.99% – Here’s What To Do Now – Marketing Sentinel - Marketing Sentinel

Feb 06, 2025

Feb 06, 2025

Stock Traders Buy Large Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS) - MarketBeat

Feb 06, 2025

Feb 05, 2025

Insider’s View: Deciphering SELLAS Life Sciences Group Inc (SLS)’s Financial Health Through Ratios - The Dwinnex

Feb 05, 2025

Feb 04, 2025

Market Analysts see SELLAS Life Sciences Group Inc [SLS] gaining to $18. Time to buy? - The DBT News

Feb 04, 2025

Feb 04, 2025

SELLAS Life Sciences Group Target of Unusually Large Options Trading (NASDAQ:SLS) - Defense World

Feb 04, 2025

Feb 03, 2025

You Should Read This Analysis Before Investing in SELLAS Life Sciences Group Inc (NASDAQ:SLS) - US Post News

Feb 03, 2025

Feb 03, 2025

Largest borrow rate increases among liquid names - TipRanks

Feb 03, 2025

Jan 31, 2025

Sellas Life Sciences Group Announces $25 Million Registered Direct Offering - Defense World

Jan 31, 2025

Jan 30, 2025

Analysts Provide An Important Insights On SELLAS Life Sciences Group Inc (SLS) - Stocks Register

Jan 30, 2025

Jan 29, 2025

SEC Form 424B5 filed by SELLAS Life Sciences Group Inc. - Quantisnow

Jan 29, 2025

Jan 29, 2025

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times

Jan 29, 2025

Jan 28, 2025

SELLAS secures $25 million in registered direct offering By Investing.com - Investing.com South Africa

Jan 28, 2025